Navigation Links
China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013
Date:6/18/2013

ed by 55.2% to RMB209.3 million ($33.7 million) from RMB134.8 million in the prior year.
  • Interest expense amounted to RMB70.1 million ($11.3 million), compared to RMB3.3 million in the prior year.
  • Net income attributable to the Company amounted to RMB112.4 million ($18.1 million), compared to RMB132.0 million in the prior year.
  • Operating cash inflow for the full year fiscal 2013 was RMB578.6 million ($93.2 million).
  • "Fiscal 2013 was a fruitful year concluded with eventful accomplishments," stated Ms. Ting Zheng, Chief Executive Officer of China Cord Blood Corporation.  "We successfully added 72,228 new subscribers to our subscriber base, finishing the year by surpassing our original target by more than 12%, and our growing accumulated subscriber base exceeded the three hundred thousand mark at 311,982.  These accomplishments were made possible by our years of market cultivation efforts and the 'Dragon Year' baby boom.  Aside from setting new records of revenue and operating cash flow, we have also raised our investment in both Guangdong and Shandong as we continue to expand our presence in China.  In addition, we are pleased that our Beijing subsidiary received AABB Accreditation as our commitment toward high quality standards has been recognized, which motivates us to strive for further quality excellence for our Group as a whole."Summary – The Fourth Quarter and Full Year Ended March 31, 2012 and 2013Three Months Ended March 31,Year Ended March 31,2012201320122013(in thousands)

    RMBRMB

    US$RMBRMB

    US$Revenues

    99,778133,011

    21,417380,490526,123

    84,711Gross Profit

    76,448106,104

    17,085293,832419,502

    67,544Operating Income

    34,84250,747

    8,172134,843209,314

    33,702Net Income Attributable to the
    Company

    29,23923,028

    3,709131,980112,447

    18,106Earnings per Ordinary Shares 
    '/>"/>

    SOURCE China Cord Blood Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. RAPS Opens Offices in Singapore and China
    2. Research Report on Chinas Diabetes Drug Market, 2013-2017
    3. Research Report on Chinas Antidepressant Market, 2013-2017
    4. Research Report on Chinas Anti-Prostatic Hyperplasia (PH) Drug Market, 2013-2017
    5. China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results
    6. Elsevier Signs Strategic Collaboration Agreement with Peoples Medical Publishing House, China
    7. Infinata's BioPharm Insight Global Editor Kim Ha to Moderate Panel at 3rd Annual U.S.-China Conference on Strategies for Mining Profits from Pharma Opportunities in China
    8. China Engineering Plastics Industry will Reach US$5 Million By 2017 - Engineering Plastics Market, Share, Size, Analysis, Market Scale, Competition and Forecast 2013-2017
    9. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
    10. Future Course of New Lethal Avian Flu Outbreak in China Can Be Predicted
    11. China Cord Blood Corporation Received AABB Accreditation
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... August 3, 2015 E-QURE Corp. ... of its Bio-electrical Signal Therapy device ("BST Device"), a ... hard to heal chronic wounds, today announced that the ... an Israeli distributor specializing in medical devices, for the ... Chemipal is a 70 years old, sales, marketing and ...
    (Date:8/3/2015)... Aug. 3, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... on the development of autologous cell therapies, announced today that ... the InvestMNT conference held in Minneapolis, Minnesota ... time. Hall,s presentation will highlight RepliCel,s 18-month milestones including CE ... Europe , clinical data from both RCT-01 (tendon) ...
    (Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
    (Date:7/30/2015)... ... , ... Ralco is honored to announce that it is the primary sponsor ... August 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the ... their daily lives. This unique exhibit also features a birthing center for fair goers ...
    Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
    ... NEEDHAM, Mass., Jan. 22 Hospitals and ... procedures that allow,construction projects to take place ... free white paper that addresses these challenges ... The white paper, titled "Infection Control ...
    ... Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ... with,Ortho Women,s Health & Urology, Division of ... settle the,outstanding patent litigation involving Ortho Women,s ... LO (norgestimate/ethinyl,estradiol). The United States District Court ...
    ... Speed in Reaching First Clinical Milestone Validates Approach, ... today,announced the successful completion of its first clinical ... for SYN-111,(rufinamide), a sodium channel blocker. Rufinamide was ... by Eisai in Europe as a,drug to treat ...
    Cached Biology Technology:White Paper Details Infection Control Challenges Hospitals Must Address During Construction 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 2Barr and Ortho Women's Health & Urology in Discussions to Settle ORTHO TRI-CYCLEN(R) LO Patent Litigation 3Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3
    (Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
    (Date:7/7/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... announces a revised version of one of its first 30 second ... CNBC in New York , Chicago ... San Francisco metro areas.    , , ... replace all the cards in your wallet and keep your identity ...
    (Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
    Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
    ... altered osteoporosis drug may be useful in fighting malaria, researchers ... other parasitic protozoa, the drug readily crosses into the red ... The drug works at very low concentrations with no observed ... Proceedings of the National Academy of Sciences . ...
    ... A group of scientists from across the world have come ... into how fructose causes obesity and metabolic syndrome, more commonly ... performed in lab animals, researchers found that fructose can be ... One form appears to be responsible for causing how fructose ...
    ... CA--A study of the tropical coral reef system along the ... could threaten the long-term health of the reefs. Led by ... was published in the journal Coral Reefs (online ... loss of predatory fish leads to a cascade of effects ...
    Cached Biology News:Modified bone drug kills malaria parasite in mice 2Research offers insight to how fructose causes obesity and other illness 2Coral reef study traces indirect effects of overfishing 2
    anti-achaete...
    P8B1...
    Mouse monoclonal [X223] to Lamin B1 + B2 - Nuclear Envelope Marker ( Abpromise for all tested applications). entrezGeneID: 4001 SwissProtID: P20700...
    Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
    Biology Products: